Enhanced assay granted approval by New York State’s Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ is the only DLBCL MRD ...
During a Case-Based Roundtable® event, Natalie Galanina, MD, reviewed how outcomes have changed in patients with primary ...
(RTTNews) - Adaptive Biotechnologies Corp. (ADPT), Tuesday announced the launch of an enhanced version of its clonoSEQ assay for measurable residual disease or MRD detection in diffuse large B ...
GlobalData on MSN11d
Foresight announces trial launch for cHL treatment with ctDNA-based MRD test“The PRECISE-HL trial represents a significant milestone in our pursuit of using MRD to personalise therapy for patients.
Adaptive Biotechnologies (ADPT) has launched an upgraded version of its clonoSEQ assay for measurable residual disease detection in diffuse ...
clonoSEQ is the only DLBCL MRD assay available for clinical use and covered by Medicare SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a ...
SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback